Swiss drugmaker Roche (ROG: SIX) has presented detailed results from the Phase III IMpassion031 study of Tecentriq (atezolizumab), at the European Society for Medical Oncology (ESMO) virtual congress.
Adding to top-line results presented earlier in the year, the study tested a combination of the checkpoint blocker and chemotherapy in triple-negative breast cancer (TNBC).
The results show a statistically-significant and clinically-meaningful improvement, with pathological complete response (pCR) of 57.6%, compared with 41.1% in the placebo plus chemo group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze